Patents by Inventor Ronald Charles Bernotas

Ronald Charles Bernotas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1-HETEROCYCLYLALKYL-3-SULFONYLAZAINDOLE OR -AZAINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
    Publication number: 20080306106
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: July 2, 2008
    Publication date: December 11, 2008
    Applicant: Wyeth
    Inventors: Ronald Charles Bernotas, Steven Edward Lenicek, Hassan Mahmoud Elokdah, David Zenan Li
  • 1-Heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 7411064
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: August 12, 2008
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Steven Edward Lenicek, Hassan Mahmoud Elokdah, David Zenan Li
  • AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
    Publication number: 20080114023
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: November 16, 2007
    Publication date: May 15, 2008
    Applicant: Wyeth
    Inventors: Ronald Charles BERNOTAS, Derek Cecil Cole, William Joseph Lennox
  • Oxazinan-2-one derivatives useful as PR modulators
    Publication number: 20080045518
    Abstract: Compounds of the following structure are described: wherein R1-R6, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.
    Type: Application
    Filed: August 13, 2007
    Publication date: February 21, 2008
    Applicant: Wyeth
    Inventors: Thomas Joseph Commons, Andrew Fensome, Gavin David Heffernan, Casey Cameron McComas, Richard Page Woodworth, Michael Byron Webb, Michael Anthony Marella, Edward George Melenski, Ronald Charles Bernotas
  • Oxazolidine derivatives as PR modulators
    Publication number: 20080045579
    Abstract: Compounds of the following structure are described: wherein R1-R6, m, V, W, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.
    Type: Application
    Filed: August 13, 2007
    Publication date: February 21, 2008
    Applicant: Wyeth
    Inventors: Thomas Joseph Commons, Andrew Fensome, Gavin David Heffernan, Casey Cameron McComas, Richard Page Woodworth, Michael Byron Webb, Michael Anthony Marella, Edward George Melenski, Ronald Charles Bernotas
  • Oxazolidone derivatives as PR modulators
    Publication number: 20080045556
    Abstract: Compounds of the following structure are described: wherein R1, R2, R5, R6, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.
    Type: Application
    Filed: August 13, 2007
    Publication date: February 21, 2008
    Applicant: Wyeth
    Inventors: Thomas Joseph Commons, Andrew Fensome, Gavin David Heffernan, Casey Cameron McComas, Richard Page Woodworth, Michael Byron Webb, Michael Anthony Marella, Edward George Melenski, Ronald Charles Bernotas
  • Tricyclic oxazolidone derivatives useful as PR modulators
    Publication number: 20080045578
    Abstract: Compounds of the following structure are described: wherein R1-R6, R16, m, V, W, X, Y, and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.
    Type: Application
    Filed: August 13, 2007
    Publication date: February 21, 2008
    Applicant: Wyeth
    Inventors: Thomas Joseph Commons, Andrew Fensome, Gavin David Heffernan, Casey Cameron McComas, Richard Page Woodworth, Michael Byron Webb, Michael Anthony Marella, Edward George Melenski, Ronald Charles Bernotas
  • Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 7297705
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor
    Type: Grant
    Filed: August 19, 2004
    Date of Patent: November 20, 2007
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Derek Cecil Cole, William Joseph Lennox
  • Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands
    Patent number: 7291736
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor
    Type: Grant
    Filed: July 22, 2004
    Date of Patent: November 6, 2007
    Assignee: Wyeth
    Inventors: Derek Cecil Cole, Ronald Charles Bernotas
  • Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 7259165
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: August 21, 2007
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Yinfa Yan
  • Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
    Patent number: 7238696
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: July 3, 2007
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Yinfa Yan, Albert Jean Robichaud, Guangcheng Liu
  • 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands
    Patent number: 7074792
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: October 12, 2004
    Date of Patent: July 11, 2006
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Steven Edward Lenicek, Schuyler Adam Antane
  • 1-heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 7057039
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: July 17, 2003
    Date of Patent: June 6, 2006
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Steven Edward Lenicek, Hassan Mahmoud Elokdah, David Zenan Li
  • 1-heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 6995176
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: July 17, 2003
    Date of Patent: February 7, 2006
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Steven Edward Lenicek
  • 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands
    Patent number: 6825212
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: November 30, 2004
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Steven Edward Lenicek, Schuyler A. Antane
  • Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 6800640
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: October 5, 2004
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Derek Cecil Cole, William Joseph Lennox
  • Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
    Publication number: 20040167122
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: February 13, 2004
    Publication date: August 26, 2004
    Applicant: Wyeth
    Inventors: Ronald Charles Bernotas, Yinfa Yan, Albert Jean Robichaud, Guangcheng Liu
  • Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
    Publication number: 20040167030
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: February 13, 2004
    Publication date: August 26, 2004
    Applicant: Wyeth
    Inventors: Ronald Charles Bernotas, Yinfa Yan
  • Method for the isolation of sulfuric acid mono-[3({1-[2-(4-fluorophenyly)-ethyl]-piperidin-4-yl}-2-methoxy-phenyl}ester
    Publication number: 20040152900
    Abstract: The present invention is directed to the method of isolation of sulfuric acid mono-[3-({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester, a metabolite of the 5HT2A antagonist (+)-&agr;-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol.
    Type: Application
    Filed: January 20, 2004
    Publication date: August 5, 2004
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Ronald Charles Bernotas, Paul Wayne Brown, Gary Thomas Emmons, Chi-Hsin Richard King
  • 1-(aminoalkyl)-3-sulfonylindole-and-indazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 6727246
    Abstract: The present invention provides compounds of formula I and the use thereof for the treatment of central nervous system disorders related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: April 27, 2004
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Steven Edward Lenicek, Schuyler A. Antane, Ping Zhou, Yanfang Li